The global pegfilgrastim biosimilar market is expected to grow at a significant CAGR during the forecast period (2021-2027).  The global pegfilgrastim biosimilar market is expanding as the number of people diagnosed with various diseases, such as cancer and HIV/AIDS, rises. Pegfilgrastim biosimilars are used to treat low blood neutrophil levels as well as to combat infections in people who have had radiation therapy or chemotherapy. As they are less expensive than pegfilgrastim, pegfilgrastim biosimilar are gaining popularity across the globe. The market is expected to grow rapidly in the next years owing to the increase in the prevalence of HIV/AIDS. As per HIV, Gov, around 5,000 young women between the ages of 15 and 24 get infected with HIV every week across the globe. In 2020, women and girls accounted for 63% of all new HIV infections in Sub-Saharan Africa. Since the peak in 2004, AIDS-related mortality has decreased by 64%, and by 47% since 2010. The AIDS-related disease claimed the lives of roughly 680,000 persons globally in 2020, compared to 1.3 million in 2010.

The majority of HIV-positive people live in low- and middle-income nations. Eastern and southern Africa had 20.6 million HIV-positive people (55%), Asia and the Pacific had 5.7 million (15%), western and central Africa had 4.7 million (13%), and Western and Central Europe and North America had 2.2 million (6%). In 2020, there were roughly 37.7 million HIV-positive people across the globe. There were 36 million adults and 1.7 million children aged 0 to 14 years among them. Women and girls made up more than half of the participants (53%). Filgrastim drug is extensively used for the treatment of low levels of blood neutrophils that occurred due to radiation poisoning, HIV/AIDS, chemotherapy, or another source. Therefore, rising prevalence of HIV is driving the growth of the market. Pegfilgrastim biosimilars are expected to be driven by government initiatives to produce biosimilars. The Australian government is committed to the Biosimilar Awareness Initiative, and in 2018 they strengthened their commitment by awarding a $5 million grant to the Generic and Biosimilar Medicines Association to support increased general biosimilar education and activities that promote appropriate biosimilar dispensing, prescription, and use.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Application 

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Pfizer Inc, Novartis International AG (Sandoz Inc.), and Fresenius SE & Co. KGaA, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Pegfilgrastim Biosimilar Market Report by Segment

By Application 

• Chemotherapy Treatment
• Transplantation
• Others

By Distribution Channel

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

Global Pegfilgrastim Biosimilar Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa